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1. Introduction
The kallikrein-kinin system is an extensively studied biological pathway and involves a multi-
protein complex, which includes serine proteinases from tissue and plasma. These proteinases
act on substrates as kininogens (high and low molecular weight), releasing the active kinins.
The main kinin is the nonapeptide bradykinin (BK).
Several studies aiming to evaluate the biological activities of the kinins revealed that this
peptide is implicated in diverse physiological processes as regulation of blood pressure,
cardiac, and renal function. Due to its ability to increase the vascular permeability by acting
on endothelial cells, BK is correlated to several pathological processes including inflammation.
These actions have been observed and described in both mammals and rodents [1].
The knowledge on the role of BK in various biological pathways as coagulation cascade, blood
pression regulation, and central nervous system modulation and signaling has been signifi‐
cantly improved, leading to the identification of BK receptors and posterior development of
drugs targeting its pathways [2].
This research was mainly driven by scientific studies on animal venoms, which lead to the
identification of the BK-related peptides (BRPs). The best, and maybe also the first, example
of such contribution was the discovery of the bradykinin-potentiating peptides (BPPs), first
described in Bothrops jararaca venom [3, 4]. The BPPs are proline-rich oligopeptides that inhibit
the angiotensin-converting enzyme (ACE), and that are responsible for the hypotensive effect
of the Bothrops genus snake venoms. The pharmacological effects of these peptides have been
studied since 70’s [3, 4], and allowed not only to the discovery of the neuropeptide BK [5], but
also to the development of the first active site-directed inhibitor of ACE as drug for the
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treatment of human hypertension [6]. In fact, several other drugs derived from venom toxins,
with or without modifications, are also commercially available (e.g. Captopril, Ancrod, and
Prialt) [7]. Moreover, the study of toxins has widely contributed to the identification of new
targets with therapeutic potential in mammals, as well as it has allowed to the understanding
and discovery of the biochemical pathways involving these targets.
Since then, the BPPs/BRPs have been found in several snake venoms, and also in wasps and
frogs, by using either biochemical or/and recombinant DNA techniques [8-11]. For instance,
molecular cloning studies using cDNA libraries of four species of snakes from Crotalinae
family showed evidences that these bioactive peptides are expressed by orthologous genes
[12]. The cloning of orthologous precursors from different snakes from Bothrops and Crotalus
genus allowed the identification of several new BPPs sequences [13-15], and some of them was
shown to display different specificity toward each active sites of the somatic ACE ectoenzyme
[16]. This was believed to be a great opportunity for the development of a new generation of
antihypertensive drugs.
The employment of recombinant DNA techniques were also fundamental to first determine
the structure of the precursor protein of BPPs, which was found to contain several sequences
of BPPs distributed as tandem repeats, followed by a C-type natriuretic peptide (CNP) at the
C-terminus of this precursor molecule [15]. In contrast to other members of the natriuretic
peptide (NP) family, CNP is synthesized in the brain and has hypotensive effect with no
significant diuretic or natriuretic actions [17]. Moreover, Northern blot analysis of several
snake tissues demonstrated the presence of similar BPPs-CNP precursor mRNA in non-
venomous tissues, such as the central nervous system (CNS) [14]. In situ hybridization studies
also detected the presence of the BPP/CNP-precursor mRNA in regions of snake brain
correlated with neuroendocrine functions, such as the ventromedial hypothalamus, paraven‐
tricular nuclei, paraventricular organ, and subcommissural organ [14]. Analogous CNP
precursor mRNAs was also described in similar regions in rat and human brains [18].
These studies suggesting the potential expression of BPPs in snake CNS stimulated us to
investigate the putative target(s) of these peptides. Based on the in vivo biodistribution studies
showing the preferential accumulation of BPPs in the rat kidney, and also a significant presence
in the brain, the first studies were conducted in theses tissues leading to the description of
several completely new potential targets and pathways, as the nicotinic acetylcoline receptors
[19], L-argininosuccinate synthase [20], and an orphan G protein-coupled receptor (GPCR)
[20]. The importance of both NO release for the antihypertensive effects of BPPs [20-22], and
also the involvement of the GPCRs, namely B2 receptor and M1 muscarinic receptor (mACh-
M1), in vasodialtion were demonstrated [23].
Together all these data collected during the last decade showed the pharmacologial signifi‐
cance of the BPPs and, more importantly, that the biological effects of these peptides, although
first believed, are not limited to the inhibiton of the somatic ACE [2]. The high variability of
molecular structures of these peptides reflecting in different specifities is an indicative that
there are still more to be discovered regarding the biological effects of this peptides family.
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In this book chapter, we intend to gather the most important results obtained up to now, thanks
to the isolation and characterization of BPPs from diverse organisms and to the knowledge
accumulated, while searching for new targets for these molecules.
2. The discovery of the snake venom BK and BRPs
The main function of snake venoms is still believed to be the immobilization of preys to ensure
feeding. The snake venoms are composed of a complex mixture of proteins and biologically
active peptides [24, 25]. The study of the pathophysiological mechanisms of poisoning and
molecular characterization of toxins from the venom of Bothrops jararaca resulted in many
scientific contributions of great importance, and among them, stand out the discovery of BK
[5] and the discovery of the first BRPs, more specifically the BPPs produced by the snake venom
glands, [4, 26] whose synergistic action is capable of causing a sharp drop in blood pressure
of small animals, for instance mammalian preys.
The BPPs are molecules able to enhance some pharmacological activities of BK, as the action
of contractile smooth muscle of guinea pig ileum evaluated in ex vivo assays [26], and also in
vivo, acting in the CNS, cardiovascular, and antinociceptive systems [27, 28]. The isolation of
the first BPPs expressed by the Bothrops jararaca venom glands was described in the early 60’s,
and they were initially coined as Bradykinin Potentiating Factors (BPF) due to their ability to
potentiate the effects of BK ignoring at that time the fact that these molecules were composed
by amino acid residues [26]. Only in early 70’s, when their primary sequence were determined,
which allowed to characterize them as peptide molecules, they were re-named as BPPs [3].
Since then, several peptides presenting similar structural characteristics have been identified
from the venom of these snakes and also from other snakes belonging to several different genus
[12, 13, 29-31]. Interestingly, they had also been described in wasps and frogs [8-11]. Typically,
the BPPs are peptides of 5-14 amino acid residues [32]. In general, all known naturally occuring
BPPs could be classified into two groups: (i) peptides of small molecular size like BPP-5a from
the venom of Bothrops jararaca, whose structural characteristic is a pyroglutamic acid at the N-
terminal and a proline residues at the C-terminal of molecule, and (ii) peptides consisting of
about ten amino acid residues, with a pyroglutamic acid at the N-terminal and a notable high
content of proline residues [32], which gives to them some resistance to hydrolysis by amino‐
peptidases, carboxypeptidases, and also endopeptidases [33].
2.1. cDNA cloning, identification and characterization of BRPs
The BK and its related peptides, e.g. the BRPs, are widely found in venomous animals, for
instance in snakes, lizards, frogs, and insects [10, 13, 34]. In general, they include several
sequences, either showing only one single amino acid substitution compared to BK or, in some
cases, presenting just a frugal sequence similarity, but with unquestionable biological/
functional correlation, for instance, acting on the same pathway or even same target protein.
In fact, these sequence variations were verified either by de novo sequencing of several BRPs
found in snake venoms [32] or by analysis of the deduced amino acid sequences of cDNAs
cloned from venomous glands [12, 14, 15], and in some cases by using both strategies [30, 34].
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The pharmacological evaluations revealed that even acting in the same pathway, they can
show distinct biological activities compared to BK, including potentiating its effects by
inhibition of its degradation or by acting on receptors and/or molecules involved in the BK
signaling pathway, including activating or blocking the BK receptors [10, 35]. As such, the
BRPs also include BPPs and the Bradykinin Inhibitor Peptides (BIPs) [13, 29, 32, 36].
2.2. BPPs and BIPs
Helokinestatins are a family of proline-rich peptides (PRPs) found originally in the lizard
venom (Heloderma suspectum) that display the function of inhibiting the BK actions on the
vascular smooth muscle [35]. Synthetic replicates of all helokinestatins were found to antag‐
onize the relaxation effect observed following BK application to a rat arterial smooth muscle
preparation, and hence, represent a family of BRPs also known as BIPs [34].
In contrast, BPPs firstly described and isolated from the venom of the Brazilian snake Bothrops
jararaca are mainly known due to their ability to potentiate the biological effects of BK [3, 26].
These BRPs are one of the most outstanding group of PRPs, as they were used as structural
and functional template/model for the development of a drug employed up to now for the
treatment of human hypertension [6].
Although functionally related to the BK and also present with the NPs in the same precursor
protein, the helokinestatins are quite different from the snake venom BPPs [12, 30, 31, 37-39].
PRPs with the same BK inhibitory characteristics have also been described in the ‘venomous’
secretion of two species of anguid lizards, the Texas alligator (Gerrhonotus infernalis) and the
Giant Hispanolian galliwasp (Celestus warreni) [38]. Although the primary structural variation of
the peptides from these species, they share several common features [34]. For instance, they
are peptides rich in prolyl residues (30-50%), which confer rigidity and order to the spatial
structure features, and also a measure of resistance to generalized proteolysis. They all possess
a Pro-Arg dipeptide motif at the C-terminus, which is quite different from the C-terminal Ile/
Val-Pro-Pro motif present in most BPPs C-terminus extremity [12]. The high degree of
conservation of these structural core features across phylogeny suggest a fundamental
biological function for this group of peptides in the lizards venoms. Among the two closely-
related species of helodermatid lizards, several helokinestatins have fully-conserved primary
structure, while several others present different sequences. Similarly to the BRPs from
amphibian skin [40] and snakes venom [13, 14, 30], helokinestatins compose tandem repeat
domains in their respective precursor proteins, probably reflecting discrete exons within the
genomic DNA. As already mentioned, some tandem repeats are composed by identical
primary structure, while some others exhibit significant amino acid substitutions. prominent
And this process of exon multiplication might facilitate the molecular diversity, by permitting
the expression of site-mutated isoforms, which is a phenomenon often described for bioactive
peptide-encoding genes, as also observed for the glucagon gene in vertebrates [41].
Cloning and alignment of cDNAs encoding BRPs precursors from the venom gland and brain
of a pit viper have allowed observing a higher degree of sequence consevation for the regions
not including the bioative peptides, and a higher variation in the primary structure of these
biological active peptides [14]. These results were shown to be in good agreement with the
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accelerated evolution hypothesis suggested by Ohno and colleagues [42]. According to this
hypothesis, the more frequent occurrence of nucleotide nonsynonymous substitutions in the
coding regions compared to the untranslated regions (UTRs) of the genes allows specific genes
to evolve in an accelerated fashion to attain unique physiological activity. On the other hand,
despite the consequent changes in the BRPs sequences observed, both the high content of
proline residues and the biological activities correlated to BK effects are still maintained (Figure
1). Another highly conserved region involves the sequence of the NPs always present in C-
terminus extremity of all known BRPs precursor proteins [12-15, 30, 31, 34, 36].
2.3. BRPs and NPs
The NP system consists of three types of hormones [atrial NP (ANP), brain or B-type NP (BNP),
and C-type NP (CNP)], and three types of receptors [NP receptor (R)-A, NPR-B, and NPR-C].
Both ANP and BNP are circulating hormones secreted from the heart, whereas CNP is basically
a neuropeptide. The NP system plays pivotal roles in cardiovascular and body fluid homeo‐
stasis. The ANP is secreted in response to an increase in blood volume, and acts on various
organs to decrease both water and Na+, resulting in restoration of blood volume. The family
of NPs were originally Na+-extruding hormones in fishes; however, they evolved to be volume-
depleting hormones promoting the excretion of both Na+ and water in tetrapods, in which both
are always regulated in the same direction. Vertebrates expanded their habitats from fresh
water to the sea or to land during evolution. The structure and function of osmoregulatory
hormones have also undergone evolution during this ecological evolution [43].
Members of the NPs family have been detected in several snake venoms, and they have been
shown to be located in the same precursor protein containing multiple BRPs sequences. While
this organization was demonstrated for many species of viperid snakes, including members
of the genera Bothrops, Crotalus, Lachesis, Agkistrodon, and Trimeresurus [12, 13, 15, 30, 31], it
may extend to some other taxa such as Bitis gabonica, that was also shown to have BPPs in their
venom [12, 13, 15, 30, 31, 44]. The presence of NPs in some elapid snakes venom (Dendroaspis)
has also been described [45]. It has been shown that the venom-derived NP precursors from
helodermatid lizard have a structural organization similar to that found in many BRPs
precursors from viperid snake venoms. However, the additionally encoded tandem-repeat
peptides are non-canonical BPPs, based on their primary structural characteristics or in terms
of the amino acid cleavage site, presenting characteristics of a recognition site typical of
propeptide convertase enzymes, that eventually might be the potential responsible for the
release of the mature BIPs from the respective biosynthetic precursors [36]. However, the BPP/
CNP biosynthetic precursors of the bushmaster (Lachesis muta), the tropical rattlesnake
(Crotalus durissus terrificus), and the massasauga rattlesnake from desert (Sistrurus catenatus
ewardsi) showed that, in addition to the classical BPPs and a NP sequence, they all also encode
single copies of a BIP exhibiting a closer structural similarity, and a propeptide convertase
cleavage site that allows the release of the BIP helokinestatins, whose sequences are
[TPPAGPDVGPR] or [TPPAGPDGGPR] [36] (Figure 1). On the other hand, putative heloki‐
nestatins peptides could not be identified in the BPP/CNP precursor of snakes as Bothrops
jararaca, Bothrops jararacussu, and Agkistrodon blomhoffi (Figure 1). The phylogenetic analysis
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Figure 1. Alignment of the amino acid sequences of BRPs precursors. Organization of the BPP/CNP and helokines‐
tatin/CNP precursor from venoms, indicating the mature BPPs (grey), helokinestatins, BIPs (red), and CNP (underlined)
Note that precursors of C. durissus, L. muta, and S. catenatus present both mature BPPs and BIPs in their sequences.
The conserved amino acid seqeunces compared to fragments involving the CNP region are highlighted (pink) and the
proline residues are indicated by boxes.
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presented here separates NPs precursor of different species into three distinct groups, those
which contain in their precursor sequence (i) only BPPs, (ii) only BIPs, and/or (iii) both BRPs,
i.e. BPPs and BIPs (Figure 1 and 2), suggesting that mutations in the coding regions of BRPs
were important for the adaptative changes along evolution of the venom system [40].
Figure 2. Phylogenetic tree based on BRP/NPs precursors. The phylogenetic analysis was performed using T-Coffee
- Multiple Sequence Alignment avaiable at http://www.ebi.ac.uk/Tools/msa/tcoffee/. In this analysis, protein sequen‐
ces of BRP/CNP precursors from reptiles were used. The NPs precursor of A. blomhoffi. B. jararaca, and B. jararacussu
contain only BPP sequences; C. warreni, G. infernalis, H. suspectum, and H. horridum contain only BIP sequences and, C.
durrissus, L. mutta, and S. catenatus contain both BRPs sequences, i.e. BPP and BIP. Despite the aligned B. martensii
sequence was partial, and therefore does not contain the sequence coding for BRPs, this species was found to express
the closest related precursor sequence to those containing only BIPs and to the B. jararaca non-coding RNA homolo‐
gous to BPP/CNP precursor.
2.4. Molecular evolution of genes encoding BRPs
Here, we take BPP/CNP and helokinestatin/CNP precursors as examples to illustrate the
evolution of a gene, since BPP/CNP precursor is also expressed in other tissues of Bothrops jararaca
besides the venom gland, incluing brain and spleen [14, 15]. A high similarity was oberved for
the BPP/CNP cDNAs isolated from brain and venom gland, although they are not identical to
each other as it should be expected [14]. Three out of the five BPP isoforms present in the brain
precursor (BPPs of 5, 10 and 13 amino acid residues) were identical to those found in the venom
gland precursor [14]. Moreover, most of insertions/deletions and point mutations were observed
within the BPP/CNP coding region, suggesting an effect of a Darwinian-type accelerated
evolution frequently observed intra-specie [42, 46] This process has been widely observed, since
a number of neuropeptides and hormones, such as the NPs [15, 47] and the vascular endotheli‐
um growth factor [48] evolved into toxins in the venom gland of poisonous animals.
It is believed that BRPs from the venom may be considered the toxin counterparts of endoge‐
nous peptides. It has also been suggested that both CNP and BPPs could be physiologically
associated, to perform fluid homeostasis and regulation of the vascular tonus, since BPP/CNP
precursor are present in regions of the snake brain showed to be involved in the control of
these activities, as described for the mammalian CNS [14].
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It is known that in the process of evolution, several mutations may occur in the genes, some of
which not affecting the mature protein sequence, while others might lead even to the genera‐
tion of messenger RNAs that are not translated into proteins. In 2000’s it was first shown that
non-coding RNAs can be involved in several roles including repression of genes, catalysis,
regulation of the development process, among others [49]. A non-coding mRNA showing a
sequence similarity to the BPPs precursor of the pit viper Bothrops jararaca was cloned by us from
the venom gland [Genbank Acc. No. AY310916.1]. This long RNA sequence does not encode a
protein, since several stop codons were observed for all possible reading frames (Figure 3).
Figure 3. Potential deduced amino acid sequences from the all possible frames of the non-coding RNA homologous
to the BPP/CNP precursor coding RNA both from Bothrops jararaca. Total mRNA obtained from Bothrops jararaca ven‐
om gland higher than 2 Kb length was used to construct the long cDNA library. The complete cDNA sequence of the
BPP/CNP precursor (clone NM 96) was used as template to screen about 2 x 106 clones, allowing the identification of
four independent positive clones containing identical inserts of approximately 3.5 Kb [15]. All potential frames of the
Bothrops jararaca BPP/CNP-related pseudogene mRNA presents a high content of stop codons (bold), as shown by the
representative amino acid deduced sequence from one of the possible reading frames. No signal peptide could ob‐
served, although several methionine (Met) residues (underlined) that does not seem to represent an initial of transla‐
tion were found.
These non-coding RNAs are usually transcribed by a gene known as a pseudogene, which are
often found in the genomes of several life forms, including bacteria, plants, insects, and
vertebrates [50]. The pseudogene is a sequence that is present in the genome, and it is typically
characterized by presenting high similarity with one or more functional gene paralogs. The
pseudogene can be derived from gene duplication occurred by two different pathways:
retrotransposition or duplication of genomic DNA [50].
The regulation of the expression of a functional gene showing sequence similarity to a
pseudogene has been reported [51]. Generally, the sequence similarity between functional
genes and pseudogenes is observed at the 5' UTR fragment. However, for the comparison of
the non-coding RNA and the RNA coding for BPP/CNP precursor, a high similarity was
observed only for the 3’ UTR sequence (Figure 4). Moreover, the non-coding RNA is of
approximately 3.5 Kb, while the RNA coding for the BPPs precursor is of about 1.8 Kb, and its
RNA expression was found to be about 6-fold higher than that of the 3.5 Kb non-coding RNA.
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Nevertheless, it is also possible that non-coding RNA of 3.5 Kb [GenBank Acc. No. AY310916.1]
may also ensures the stability of the functional coding messenger RNA, since the stability of
messenger RNAs is preferably controlled by factors present in the 3' UTR region [52].
Figure 4. Partial sequence alignment of theBothrops jararaca BPP/C NP-related pseudogene mRNA and mRNA
coding for BPP/CNP precursor. Alignment of the nucleotide sequences of a segment of the pseudogene mRNA
(non-coding: upper sequence) and the mRNA coding for BPP/CNP precursor (BPP-coding: lower sequence) was per‐
formed using the Clustaw W program, available at http://www2.ebi.ac.uk/clustalw/. Identical nucleotides are indicat‐
ed by “*” and insertions or deletions are represented by gaps (-).The boldface type letters indicate the region with
higher similarity between the RNA sequences, corresponding to about 97% identity in this region.
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In the BPP/CNP precursor of Bothrops jararaca, the pentapeptide BPP-5a [QKWAP] that was
used as template for the development of the antihypertensive drug captopril, is found
duplicated, i.e., there are two copies of the same peptide in a single precursor protein. It is
believed that this peptide might have a special importance in the venom of snakes belonging
to the Bothrops genus, since it is also found repeated three times in isoform 1 [GenBank Acc.
No. AY310914.1], and four times in isoform 2 [Genbank Acc. No. AY310915.1] of the precursors
isolated from Bothrops jararacussu venom glands (Figure 5). In fact, BPP-5a is a potent poten‐
tiator of the BK effects in isolated guinea pig ileum, and also in vivo [29].
Figure 5. Partial nucleotide and amino acid sequences of the BPP/CNP of precursor fromBothrops jararacussu
(isoform 1 and 2). Shaded in grey, the amino acid sequences of the C-type natriuretic peptide (CNP). Sequences of
new putative BPPs are shown in green, and the underlined sequences correspond to other previously known BPPs. In
red, the pentapeptide BPP-5a that was found in duplicate in the pit viper precursor and, triplicate and quadruplicate in
the isoforms 1 and 2, respectively, of the precursor from Bothrops jararacussu. Symbol “M” represents the initial me‐
thionine and (-) the stop codon.
3. BRPs as structural model for drug development
The discovery of the potential inhibitory action of BPPs on ACE brought a great interest in
these natural peptides, since the importance of ACE in blood pressure control and the urge to
develop a therapy for cardiovascular disease, as hypertension, was iminent [2].
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At that time, among the identified peptides were BPP-9a, under the generic name of teprotide,
and the BPP-5a, which was also one of first BPP to be characterized. Assays using these
peptides showed that BPP-9a was more effective and had a longer lasting effect in blood
pressure compared to BPP-5a [53]. Therefore, BPP-9a was used in the first clinical demonstra‐
tion of the potential use of BPPs for the hypertension control in humans, showing a significant
antihypertensive effect [54, 55].
However, on that time it was demonstrated that the therapeutic utility of BPP-9a was limited
by the lack of activity by oral administration and the high cost of its synthesis [54, 56, 57].
Therefore, the pharmaceutical development of a non-peptide inhibitor of ACE orally effective
was essential. Thus, molecular structure of the BRPs, namely BPP-5a and BPP-9a, were studied
by Cushman and Ondetti [3, 58], who suggested specific interaction of the proline, present at
the C-terminal of these peptides, with the ACE active site [59]. Thus, captopril was synthetized
by simple addition of a chelator radical to a dipeptide containing a proline residue (BPP
carboxy-terminal amino acid) [59]. Unodoubtely captopril was a blockbuster drug that
inspired the creation of generations of mimetic antihypertensive compounds [2].
4. Biological activities of BRPs
4.1. Interference of BRPs in the renin-angiotensin and kallikrein-kinin system
The ACE (EC 3.4.15.1) is mainly expressed in vascular endothelium in epithelial cells of the
proximal tubules of the kidney, brain, and intestinal cells [60]. This enzyme is responsible for
conversion of angiotensin I (Ang I) to angiotensin II (Ang II), and for the degradation of BK.
Therefore, this enzyme has roles in both renin-angiotensin and kallikrein-kinin system [61].
The renin-angiotensin system (RAS) is composed by a set of peptides, enzymes, and receptors,
that are involved in the control of the extracellular fluid and blood pressure [62]. The formation
of the effector peptide of this system occurs initially by the action of the renin released by the
kidneys [62] that acts on the angiotensinogen produced in the liver [63]. This leads to the
generation of the decapeptide Ang I, which then is cleaved by ACE to form the octapeptide
Ang II, a potent antihypertensive molecule [64]. Ang II actions is mediated by the angiotensin
receptors AT1 and AT2. The binding of Ang II to the AT1 receptor triggers several cellular
processes, among them vasoconstriction, protein synthesis, cell growth, regulation of renal
function, and electrolyte balance [65]. Ang II also acts as a neurotransmitter and as a neuro‐
regulador, modulating the central control of the blood pressure, influencing the sympathetic
activity, salt appetite, and thirst [65].
The kallikrein-kinin system (KKS) is a metabolic cascade in which the tissue and plasma
kallikrein release vasoactive kinins from both high and low molecular weight kininogens. The
nonapeptide BK, derived from the cleavage of the high molecular weight kininogen by
kallikrein, is the major plasma kinin playing a role in the KKS [66].
Kinins are involved in various physiological and pathological processes, including vasodila‐
tion, increased vascular permeability, release of plasminogen activator of tissue type (t-PA),
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and nitric oxide (NO) and arachidonic acid metabolism, mainly due to their ability to activate
endothelial cells [66]. Thus, the kinins participate in the physiologically regulation of blood
pressure, cardiac and renal functions, and also in pathological processes as inflammation [66].
The several pharmacological activities of kinins are mediated basically by the their binding to
two types of specific receptors (B1 and B2 receptors), prior to their fast metabolization by
various peptidases [67].
Actions such as vasodilation and hypotension are mediated by the B2 receptor by releasing of
NO, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). On the other
hand, the actions mediated by the B1 receptors include important roles in angiogenesis,
inflammation, and septic shock [68]. Moreover, unlike B2 receptor, B1 receptor is not consti‐
tutively expressed, and its expression is induced by mediators of inflammation in conditions
of injury [68].
The primarily responsible for the degradation of BK are the peptidases (zinc metallopeptidas‐
es) including ACE [67]. Since the early 90’s, it is well known that somatic ACE has two active
sites, the N-terminus (N-site) and the C-terminus (C-site) active sites [69]. Although in vitro,
the two active sites are equally effective to convert Ang I to Ang II, as well as to degrade the
BK into BK1-7 and BK1-5 [70], the N-site is several times more effective to hydrolyze other
bioactive peptides, such as the AcSDKP, a negative regulatory factor for differentiation and
proliferation of hematopoietic stem cells [71].
Thus, ACE inhibitors as BPPs inhibit not only the generation of Ang II, but also potentiate the
effects of BK, by inhibiting its degradation. Therefore, the physiological effects of the angio‐
tensin system are decreased (since there is no formation of Ang II), and the physiological effects
of KKS are potentiated (due to inhibition of the BK degradation). In contrast, the BIPs, most
known as helokinestatins, inhibit KKS by blocking the B2 receptor (Figure 6).
4.2. Mechanisms of action underlying the antihypertensive effect of BRPs
Although ACE inhibition is a relevant mechanism to explain the activity of most BPPs, and
despite of their high primary sequence similarity [53, 72], as previously suggested, the BPPs
show remarkable wide variety of mechanistic pathways that could explain the antihyperten‐
sive activity of BPPs at molecular level [13, 14, 19, 20, 22, 23, 29, 73-76]. Definitely the biological
effects of BPPs and the consequent pharmacological importance of their activity are not limited
to and it cannot be explained solely based on their ability to inhibit ACE [2].
The differences were first observed when comparing the selectivity of the BPPs encoded by
the neuronal BPP/CNP precursor protein [e.g. BPP-5a, BPP-10c, BPP-11e, BPP-12b, and
BPP-13a] [14] by the different active sites of the somatic ACE and the corresponding biological
activity of these peptides evaluated by their ability to potentiate the contractile effect triggered
by BK in isolated guinea pig ileum. For instance, the BPP-5a was shown to be much less
effective ACE inhibitor compared to BPP-13a, although presenting one of the most potent
potentiator effects of BK in ex vivo experiments. In contrast, BPP-10c is an excellent selective
inhibitor of the C-terminal active site of somatic ACE, and its BK potentiating effect is very
similar to that observed for both BPP-5a and BPP-12b, which were shown to be selective for
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the ACE N-terminal active site. In the same way, besides the weak BK potentiation effects of
BPP-11e, it is also not among the best inhibitors of ACE, and no preference for any of the active
sites of ACE was observed for this peptide [29].
Later on, in 2007, molecular studies of the antihypertensive activity of the BPPs, namely BPP-7a
and BPP-10c, brought noteworthy information on the molecular mechanism underlying the
action of these peptides at cellular level. In fact, these BPPs have a strong and sustained
antihypertensive activity in awake spontaneously hypertensive rats (SHRs), but they do not
prevent the formation of Ang II from Ang I in vivo, showing that they do not need to affect the
physiological functions of ACE to promote the decrease of the blood pressure in these animals.
Furthermore, for BPP-10c, we have also shown that the dose necessary to produce the
antihypertensive effect is lower than that required to inhibit ACE in vivo [77], suggesting the
participation of other putative targets determining this particular pharmacological effect.
This finding was reinforced by the studies conducted to clarify the biological distribution of
BPP-10c using a I125 labeled analog, which showed that this peptide accumulated in various
rat organs such as brain, liver, testis, and kidney, even after pre-saturation of the potential
active sites of ACE with a specific inhibitor of this enzyme, namely captopril [78].
This stimulated us to conduct studies aiming to identify new potential molecular targets for
snake BPPs. So, it was shown that at least three BPPs, namely BPP-10c, BPP-12b, and BPP-13a,
are able to bind to the enzyme argininosuccinate synthase (AsS) modulating positively its
activity [20, 75].
Figure 6. Schematic representation of ACE roles on the renin-angiotensin and kallikrein-kinin systems, and the poten‐
tial sites for interference by BRPs (BPPs and BIPs). A) Conversion of angiotensin I into angiotensin II, 2) BK degradation
3) ACE inhibition by BPPs. 4) B2 receptor antagonism by BIPs. Physiological effects on the renin-angiotensin system
mediated by AT1 receptors include vasoconstriction, sodium and water retention, release of aldosterone, increased
sympathetic nerve activity, among others, while those mediated by AT2 receptors include cell differentiation, vasodila‐
tion, among others. The effects on the kallikrein-kinin system, mediated by kinins action on B2 receptor include vaso‐
dilation and hypotension via release of NO, prostacyclins and endothelium-derived hyperpolarizing factor (EDHF). Due
to the ACE inhibition by BPPs, the physiological effects of angiotensin system are decreased (with no formation of an‐
giotensin II) and the physiological effects of kallikrein-kinin are potentiated (by inhibition of BK degradation). In con‐
trast, BIPs action on B2 receptor blocked BK effects. Adapted from [132-134].
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The AsS is the rate-limiting step enzyme responsible for providing the substrate for the nitric
oxide synthase (NOS) that produces NO [79, 80]. Guerreiro and colleagues also demonstrated
that blood pressure decrease promoted in SHRs by BPP-10c administration is due to the
increased bioavailability of L-arginine required for the production of NO [20], which is a potent
vasodilator agent [81]. Later it was demonstrated that other BPPs also induces NO production
to determine the antihypertensive effect [21, 75].
Moreover, at least for the BPP-5a-induced NO production, the involvement of both B2 receptor
and mACh-M1, without any involvement of AsS, was recently demonstrated [23]. BPP-13a
induces NO production through a mechanism that involves activation of subtype M3 mus‐
carinic receptor (mACh-M3), triggering the raise of the free intracellular calcium concentration
([Ca2+]i) that is able to activate NOS and to provide the substrate for NO production by
modulating the AsS activity [75].
Both BPP-11e and BPP-12b do not stimulate NO production, but the [Ca2+]i mobilization assays
suggest that these peptides are agonists of a membrane receptor involved in the release of
EDHF, and other functions involving the modulation of gene expression and activation of
different NOS enzymes is expected [82]. As BPP-12b modulates positively AsS activity only at
very high concentrations, this should not be its main mechanism of action [75].
Since the BPP-9a has ACE as main target for its biological actions, based on its potent inhibitory
activity against this enzyme also showing selectivity for the C-terminal active site [73], we
suggest that it is possible to suggest this pathway to explain the antihypertensive effect and
BK potentiation of BPP-9a (teprotide). Moreover, it has no effect on the AsS induced intracel‐
lular calcium and it also does not interfere with NO production.
Apparently all BPPs share the ability to decrease arterial pressure [21, 56, 75, 77, 83], through
the amplitude of the antihypertensive effect caused by BK, each related peptides is different.
But, unfortunately, the mechanisms of action of other BPPs are still less understood up to
now [75].
4.3. Peripheral and central biological activities of BPPs
Changes in mean arterial pressure (MAP) promoted by some BPPs are accompanied by a
significant reduction in heart rate (HR) [23, 75, 77] rather than by an HR increase, as it would
be expected by the response of the baroreceptors to the hypotension [84]. The fact is that in
bolus injections of BPPs decrease both MAP and HR of awake SHRs, and BPPs expression in
the same precursor protein of a brain expressed peptide as CNP suggests a CNS role for these
peptides. In fact, recently it was shown that the BPP-10c is able to promote the release of the
neurotransmitters GABA and glutamate, which are known to participate in the regulation of
cardiac and vascular autonomic systems, leading to decline MAP and HR of SHRs [22].
According to Lameu and collaborators, BPP-10c-induced decrease of MAP results from this
BRP-induced interference in the autonomic nervous system, provoking subsequent changes
in HR and baroreflex control [22, 74].
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Arterial baroreflex is one of the most important regulatory mechanisms in the cardiovascular
system, mainly by triggering a coordinated sympathetic and parasympathetic tone response
on the heart and vessels [85-90].
The CNS is connected to the heart through two different groups of nerves, the parasympathetic
and sympathetic systems. Stimulation of parasympathetic nerves determines the decrease of
HR, of contraction force of atrial muscle, and of conduction of impulses through the atrioven‐
tricular node, and at the same time, it also causes the increase of the time delay between the
atrial and ventricular contraction, and the reduction of blood flow through the coronary
arteries, which maintains the nutrition of the myocardium. All these effects can be summarized
by saying that the parasympathetic stimulation decreases all the activities of the heart. On the
other hand, the stimulation of sympathetic nerves has exactly the opposite effects on the heart,
leading to an increased HR, increased contraction force, and increased blood flow through the
blood vessels [87, 91].
It was observed that BPP-11e causes a slight reduction in MAP, but surprisingly with a strong
reduction in HR [75], suggesting a BPPs action in specialized muscle cells located in the sino-
atrial region (pacemaker) of the heart, which is a special region of the heart that controls the
cardiac frequency [92]. Although the heart has its own intrinsic control systems, it can operate
under neural influences, therefore effectiveness of the cardiac action can be significantly
modified by regulatory pulses from the CNS [92]. Thus there is also possible that the BPP-11e
has an effect on the stimulation of the parasympathetic system and/or in the decreasing of the
sympathetic system stimulation, leading to a reduction of the HR and a slight decrease in MAP,
observed after in vivo injection of this peptide [75].
A more detailed study of the BPPs effects on the CNS was performed for the BPP-10c, in which
intracerebroventricular administration was shown to produce similar effects to those observed
for higher doses injections of this peptide by intravenous route. In our interpretation, this data
suggested the involvement of the CNS in the pathway underlying these biological effects [74].
Aiming to explain tbe BPPs effects on CNS, Lameu et al. have also conducted studies to
demonstrate that the BPP-10c acts through activation of an unidentified Gi/o-coupled receptor
present in neuronal cells, and that this effect was independent of both ACE inhibition and B2
receptor activation. Peptide–receptor binding resulted in the activation of calcium influx and
release of intracellular calcium by calcium-induced calcium release (CICR) mechanism, which
was shown to involve the activation of the ryanodine- or IP3-sensitive calcium stores and also
the inhibition of adenylate cyclase [74]. However the specific target GPCR could not be
identified yet.
On the other hand, affinity chromatography, using immobilized BPP-10c, associated with mass
spectrometric and immunoblot analyses, allowed the identification of two important targets
of BPP-10c, namely the AsS in the kidney cytosol [20] and the synapsin in the brain (Figure
7) [93]. AsS, together with argininosuccinate lyase (AsL), is part of the urea cycle in the liver
and of the arginine-citrulline cycle, the major source of arginine in the renal cells and citrulline–
NO cycle, which is the main source of NO in other cells, including endothelial and neuronal
cells [94].
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Figure 7. Synapsin binds to BPP-10c. (A) SDS-PAGE analysis of brain rat cytosolic proteins submitted to HiTrap-
BPP-10c affinity chromatography. Rat brain cytosol preparation to affinity chromatography using the HiTrap NHS-acti‐
vated HP resin to which BPP-10c was immobilized by chemical conjugation M (KDa), molecular mass markers; lane 1,
protein eluted by competition using 5 mg of BPP-10c; lane 2, protein eluted with 100 mM glycine, 0.5 M NaCl pH 3.0
(elution buffer: by lowering the pH). (B) protein identification by mass spectrometric analysis of the bands enclosed in
the box in the panel A. The 74-kDa major protein that bounds to BPP-10c was identified as synapsin, by trypsin diges‐
tion and peptide mass fingerprint analysis.
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AsS is a ubiquitously expressed enzyme, present in many tissues, including brain and kidney
[94]. In vivo BPP-10c administration in SHRs animal models results in increase of plasma
arginine level [20] and augmented NO production in brain tissues, as well as in neuronal and
endothelial cells [20, 22].
NO is generated in the citrulline-NO cycle by NO synthase (NOS) using L-arginine as a
substrate. Three isoforms of NOS have been described: Ca2+-dependent endothelial (eNOS)
and neuronal (nNOS) isoforms [95] and inducible NOS. The expression and activity of the
latter are induced by inflammatory stimuli,  independent of  the cytosolic Ca2+  concentra‐
tion [96].
NO is mainly involved in the regulation of local and systemic vascular resistance in sodium
balance, and hence in blood pressure control [97], since it is one of the smooth muscle relaxing
factors released by the endothelium, which diffuses to the adjacent smooth muscle cells
promoting vasodilatation [98, 99].
Nevertheless, NO has been attributed to other various functions, including non-cholinergic
and non-adrenergic smooth muscle relaxation, reduction of arterial pressure, and signal
transmission in the CNS [100]. NO-mediated actions in the CNS include central vascular
regulation [101] and baroreflex control of HR [102]. Antihypertensive activity, based on the
facilitated release of both GABA and glutamate in the CNS and NO production, is suggested
to result in the diminished transmission of sympathetic tone to the periphery [101, 103].
Treatments with BPP-10c also induced an increase in AsS gene expression [22]. In contrast,
nNOS was not found differentially expressed in the brains of SHRs treated with BPP-10c
compared to vehicle-treated animals. On the other hand, the gene expression levels of eNOS,
similarly to those of AsS, were found increased in the brains of SHRs animals treated with
BPP-10c [22]. This data is in line with the results obtained by Kishi and colleagues [104] who
were able to show that the overexpression of eNOS in the rostral ventrolateral medulla and
the nucleus of the solitary tract of hypertensive rats results in reduced systolic arterial pressure
and reduced HR.
However, the specificity of NO reactions with neuronal targets is determined in part by the
precise localization of NOS within the cell. The targeting of NOS to discrete nuclei of neurons,
mediated by adapter proteins, allowed to suggest that both synapsin and NOS participate of
a ternary complex, which changes in the subcellular localization of NOS [105].
Knowing that the BPP-10c binds to synapsin in the CNS, we hypothesized the formation of a
quaternary complex upon binding of BPP-10c with synapsin. The formation of this complex
would direct the reactions of NO in neural targets, which would be determined in part by the
location of this complex and by targeting NOS to specific sites of neurons [105].
We were able to show that BPP-10c is capable to induce intracellular Ca2+ signaling that
involves the activation of GPCRs, NO production, and release of neurotransmitters, such as
GABA and glutamate [22, 74]. The amino acid glutamate is the major excitatory neurotrans‐
mitter in the CNS of mammals, whereas GABA is the main mediator of sympathetic inhibitory
currents. Both glutamate and GABA play key roles in the control of cardiovascular function
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in the CNS [103]. Excitatory amino acid neurotransmitters, like glutamate and aspartate,
generally cause pressure responses and tachycardia, while inhibitory amino acid neurotrans‐
mitters, namely GABA and glycine, are responsible for depressing bradycardia [104]. It is well
established that the excitatory amino acid glutamate is considered the main neurotransmitter
of primary afferent fibers of baroreceptors to the nucleus tractus solitarii (NTS) [106]. Further‐
more, an excitatory projection from NTS to the caudal ventrolateral medulla (CVLM) is an
essential part of the circuit of baroreflex control. The CVLM communicates with the rostral
ventrolateral medulla (RVLM) by secretion of GABA. In addition to GABAergic inhibition of
RVLM, excitatory amino acids are also known to exert important roles in cardiovascular
regulation [107]. These neurotransmitters can regulate vasodilatation through reduction of
both sympathetic activity and baroreflex sensitivity control, by acting on regulation of both
sympathetic and parasympathetic systems. Therefore, the augmented baroreflex sensitivity
by i.v. injection of BPP-10c is attributted to the release of these neurotransmitters [22, 74]. These
data is summarized in Figure 8.
Figure 8. Schematic representation of BPP-10c mechanism of action in the CNS. According to [22, 74, 93], the pro‐
posed mechanism to explain the BPP-10c effects on the blood pressure (BP) and heart rate (HR) in spontaneously hy‐
pertensive rats (SHRs) was summarized in this figure. First, BPP-10c-induced [Ca2+]i elevations activates signaltransduction pathways responsible for the increased nitric oxide synthase (NOS) activity and the expression of the en‐
zymes, namely endothelial NOS (eNOS) and argininosuccinate synthase (ASS). It also triggers the release of the neuro‐
transmitters GABA and glutamate. After the BPP-10c internalization by neuronal cells, this peptide binds to synapsin
to control the release of GABA and glutamate, and to direct the NOS to discrete cores of the neurons. Furthermore,
BPP-10c can positively activate the AsS functions to increase the levels of L-arginine. NO production due to increased
concentration of L-arginine, NOS activation, and increased expression of eNOS and AsS should contribute for the re‐
lease of neurotransmitters and also for the regulation of autonomous activity. Likewise GABA and glutamate deter‐
mine the reduction of both blood pressure and heart rate, and the increases of the baroreflex sensitivity in SHRs.
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The fact of BPPs decrease the HR does not mean that its action is limited to the CNS. Taking
the example of BPP-10c, in vivo biodistribution studies showed a significant presence of this
peptide in the brain, however accumulation was also observed in the rat kidney [78]. Consid‐
ering its high accumulation in kidneys with the fact that BPP-10c induces NO production in
endothelial cells [20, 108] and the increase of plasma L-arginine level in vivo [20], we conclude
that this peptide, and also potentially the other BPPs, may display both peripheral and central
actions.
Moreover, there might exhist BPPs with exclusive peripheral action. As suggested for BPP-9a
that promotes discret decrease of MAP and does not affect HR [75], whose effects were possible
to be explained solely based on the classical mechanism of action suggested for the BPPs, i.e.,
relying in the selective inhibition of the somatic ACE [73].
The pharmaceutical compositions for the applications in chornic-degenerative diseases and
hypertension of the BPPs and their structural and/or conformational analogs, as well as the
isolation and purification of BRPs secreted by snake venom glands are protected by the patents
US20050031604 and US20080199503. The inventions further refer to pharmaceutical composi‐
tions that increase the biodisponibility and efficacy of BRPs peripheral and central biological
activities. BRPs allowed the development a successful oral drug to treat human hypertension,
but they also have the potential to become a drug by itself or a drug model to develop
compouds devoted to treat central nervous system diseases, once pharmaceutical composi‐
tions that allow efficient delivery in vivo of these BRPs is achieved.
4.4. Mechanism of action that underlies the hyperalgesia and inflammatory responses
For many years it has been known that BK is an inflammatory mediator involved in the
nociceptive process [109]. BK and also the BRPs produce pain and hyperalgesia due to their
ability to excite and/or sensitize nociceptors [10].
In particular, two novel BRPs named fulvonin [SIVLRGKAPFR] and cyphokinin
[DTRPPGFTPFR] were recently described in wasp (Cyphononyx fulvognathus). They could be
structurally and functionally considered as BRPs, since they both are able to inhibit ACE as
well as to induce the hyperalgesic effect in living rats after intraplantar injection, mostly due
to the agonist action of these peptides on distinct B2 or B1 receptors, respectively [10].
5. Potential and effective pharmaceutical applications
5.1. Application of BPPs to treat CNS disorders and hypertension
In  the  last  few  years,  as  presented  here,  it  was  possible  to  describe  a  number  of  new
mechanisms of action for BRPs previously known only as potent ACE inhibitors. Taking
this into account, many pharmaceutical applications could be possible suggested for these
peptides solely based on the treatment of pathologies related with their targets, for instace
the somatic ACE, AsS and so on.
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Regarding AsS as a novel potential target for the development of new drugs based on BPPs
structural model, it is worth mentioning that its action on L-arginine metabolims contributes
to three main functions in the organism, depending on the cell or tissue type involved,
including effects on detoxification of ammonia in the liver, production of L-arginine in the
kidney to be distributed to the whole organism, and the synthesis of L-arginine for the
production of NO in several other cells [94]. In addition to these three major functions, it has
also been suggested that AsS plays an important role in neuromodulation by producing
argininosuccinate [110].
Due to its involvement in biochemical processes that generate physiological impacts on the
organism, AsS is of great clinical value since its deficiency or excessive expression has been
associated with some diseases, such as citrullinemia [111], hypertension [112, 113], and
Alzheimer's disease [114, 115].
Since, AsS also participates in the L-arginine recycling, which contributes to the maintenance
of NOS substrate,and AsS catalytic activity is considered the limiting step for NO production
[116], the upregulation of this enzyme restores the balance of that system with consequent
reduction in blood pressure [20].
Moreover, the identification of acetylcholine receptors as novel putative targets responsible
for the vasodilatation promoted by the BRPs [19, 23, 75] also opens new avenues to the
development of possible future therapeutic applications of BRPs related compounds for CNS
diseases treatment.
Different experimental approaches demonstrate that acetylcholine muscarinic receptors are
present in virtually all organs, tissues and cell types. The muscarinic receptors in the CNS are
involved in the regulation of an extraordinary number of cognitive, behavioral, sensory, motor,
and autonomous functions. Reduced or increased signalling of different subtypes of muscar‐
inic receptors are involved in the pathophysiology of several diseases of the CNS including
Alzheimer's and Parkinson's diseases, depression, schizophrenia, and epilepsy [117].
The contribution of the muscarinic acetylcholine receptor, mAchR-M1, in the NO production
stimulated by BPP-5a is therapeutically and scientifically interesting, since much effort has
been undertaken in the search for mAchR-M1 agonists to treat cognitive disorders including
the Alzheimer’s disease [118, 119].
On other hand, the mAchR-M3 is mainly involved in the control of vascular tone. The main
actions mediated by these peripheral  muscarinic  receptors  include the reduction of  HR,
stimulation of glandular secretion, and smooth muscle relaxation [117].  Compounds that
activate  this  receptor  to  promote  vasorelaxation,  such  as  pilocarpine,  are  used  for  the
treatment of glaucoma, ocular hypertension [120, 121]. However, the BRPs as BPP-13a is
not  only  able  to  activate  mAchR-M3,  but  in  the  same time  it  acts  modulating  the  AsS
activity. Since both pathways contribute to the antihypertensive effects by controlling the
NO production, BPP-13a represents a potent vasodilator compound with potential broad‐
er applications in the medicine [75].
Taking together, the comparison of the biological actions of BRPs found in the venom and
brain of the pit viper Bothrops jararaca with those from different species, allowed us to describe
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that, contrary to what was thought for several decades, these peptides have different biological
effects and therefore are an inexhaustible source of powerful biological tools not only for the
study and discovery of new physiological pathways, but also as potentially useful compounds
for new drug development.
Therefore, a patent protecting the use of these oligopeptides capable of binding to diverse
targets, determining the increase and the sustenance of nitric oxide (NO) production in
mammalian cells by potentiating the endogenous argininosuccinate synthase activity present
in animal cells and/or by increasing the intracellular bivalent free calcium ion in the cytosol of
cells was filed (US20100035822). Pharmaceutical compositions containing one or more of these
peptides is also described and also disclosed in this same patent.
5.2. Application of BIPs in the treatment of pain and inflammation
NO is involved in vasodilatation and in many other physiological processes. Several lines of
evidence have indicated that NO plays a complex and diverse role in the modulation of pain
[122]. It has been shown that NO mediates the analgesic effect of opioids and other analgesic
substances, opening opportunities of potential use of molecules able to regulate NO produc‐
tion in pain therapy. Modification of pre-existing analgesic and anti-inflammatory drugs by
addition of NO-releasing moieties has been shown to improve the analgesic efficacy of these
drugs, and also to reduce their side effects [123].
NO donors have also been used with opioids to reduce pain in patients with cancer [124]. This
strategy enhances the analgesic efficacy of morphine in patients with cancer pain, delaying the
morphine tolerance and decreasing the incidence of the adverse effects of opioids [88, 125].
Nevertheless, the use of NO donors should be carefully evaluated, since the excessive levels
of NO production can be deleterious to the organism [126]. Soon, keeping NO production at
a safe level, avoiding the deleterious threshold, is of particular interest.
Therefore, the BRPs that modulate AsS activity [20, 75] could be considered for pain treatment.
The fact that this AsS activity interferes with L-arginine metabolism, a source of NO synthesis
that has its own levels subjected to very precise mechanisms of physiological control, repre‐
sents the most likely target able to regulate NO production without generating undesired
reactive by-products (review by [127]).
Other family of BRPs, which should be considered in the treatment of pain and inflammation,
are the antagonists of BK receptors (BIPs), namely helokinestatins. Although these BRPs were
described as vasoactive peptides, due to their ability to antagonize the relaxation effect induced
by BK [35, 36], they could potencially be employed in the therapy of hyperalgesia.
Kinins formed following tissue trauma and in inflammatory processes, acting by means of
the activation of B2 receptors,  are among the most potent endogenous algogenic media‐
tors. Kinins through action on BK receptors can release a large number of inflammatory
mediators, such as prostaglandins and neuropeptides such as neurokinins [128], that in turn
amplify the nociceptive response. Therefore, these receptors play an important role in pain
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transmission.  BK produces a short-lived hyperalgesia,  while des-Arg9-BK causes a long-
lasting hyperalgesia [1].
However, most of the B2 receptor antagonists present partial agonist activity and fail to
produce antinociception when given orally [1]. Non-peptide B2 receptor antagonists, although
they are generally less potent when compared with Hoe 140, for instance, produce long-lasting
oral antinociception with no evidence of partial agonistic activity [129-131]. In this way, further
studies of BRPs applied in the pain treatment could provide valuable information for the
development of novel peptidic or non-peptidic molecules to effectively relieve the pain of
human patients.
The BRPs isolated from toad (Bombina maxima) defensive skin secretion, and their analogs
thereof, prodrugs including the peptides, pharmaceutical compositions are protected by
patent WO2004/068928. These BRPs and analogs thereof are antagonists of B2 receptor and
they can be used to treat and/or prevent disorders associated with BK, including cardiovas‐
cular disorders, inflammation, asthma, allergic rhinitis, angiogenesis, pain and related
pathologies.
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